J&J Opens New 340B Litigation Front With Lawsuit Against HRSA Over Rebate Model

 
• By Cathy Kelly

Company’s move against the US agency tasked with overseeing the 340B drug discount program is the latest in a series of manufacturer attempts to rein in ballooning 340B price concessions.

Manufacturers countering HRSA enforcement threats in court. (Shutterstock)

More from Pink Sheet

More from Market Access